Evidence map›Paper›PMID 28055971›Full record

ArticleOncotarget2017

Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.

Indranil Chattopadhyay, Jianmin Wang, Maochun Qin, Lingqiu Gao, Renae Holtz, Robert L Vessella, Robert W Leach, Irwin H Gelman

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Indranil ChattopadhyayDepartment of Life Sciences, School of Basic and Applied Science, Central University of Tamil Nadu, Thiruvarur, Tamil Nadu, India.
Jianmin WangDepartment of Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Maochun QinDepartment of Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Lingqiu GaoDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Renae HoltzDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Robert L VessellaDepartment of Urology, University of Washington, Seattle, WA, USA.
Robert W LeachLewis-Sigler Institute for Integrative Genomics, Princeton, NJ, USA.
Irwin H GelmanDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Roswell Park Comprehensive Cancer Center · USCancer Genetics (United States) · USCentral University of Tamil Nadu · INPrinceton University · USUniversity of Washington · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin/AKAP12R01CA094108 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GELMAN, IRWIN H. · 2002 to 2014
$2.8M
PKC/PKA in Prostate CancerR55CA094108 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GELMAN, IRWIN H. · 2002 to 2002
$100k
NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA094108NCI NIH HHS R55 CA094108
6 · The paper itself

Abstract

Progression of prostate cancer (PC) to castration-recurrent growth (CRPC) remains dependent on sustained expression and transcriptional activity of the androgen receptor (AR). A major mechanism contributing to CRPC progression is through the direct phosphorylation and activation of AR by Src-family (SFK) and ACK1 tyrosine kinases. However, the AR-dependent transcriptional networks activated by Src during CRPC progression have not been elucidated. Here, we show that activated Src (Src527F) induces androgen-independent growth in human LNCaP cells, concomitant with its ability to induce proliferation/survival genes normally induced by dihydrotestosterone (DHT) in androgen-dependent LNCaP and VCaP cells. Src induces additional gene signatures unique to CRPC cell lines, LNCaP-C4-2 and CWR22Rv1, and to CRPC LuCaP35.1 xenografts. By comparing the Src-induced AR-cistrome and/or transcriptome in LNCaP to those in CRPC and LuCaP35.1 tumors, we identified an 11-gene Src-regulated CRPC signature consisting of AR-dependent, AR binding site (ARBS)-associated genes whose expression is altered by DHT in LNCaP[Src527F] but not in LNCaP cells. The differential expression of a subset (DPP4, BCAT1, CNTNAP4, CDH3) correlates with earlier PC metastasis onset and poorer survival, with the expression of BCAT1 required for Src-induced androgen-independent proliferation. Lastly, Src enhances AR binding to non-canonical ARBS enriched for FOXO1, TOP2B and ZNF217 binding motifs; cooperative AR/TOP2B binding to a non-canonical ARBS was both Src- and DHT-sensitive and correlated with increased levels of Src-induced phosphotyrosyl-TOP2B. These data suggest that CRPC progression is facilitated via Src-induced sensitization of AR to intracrine androgen levels, resulting in the engagement of canonical and non-canonical ARBS-dependent gene signatures.

Indexed as

Transcription, GeneticTranscriptomeAndrogen AntagonistsBinding SitesCell Line, TumorCell ProliferationDihydrotestosteroneDisease ProgressionDose-Response Relationship, DrugDrug Resistance, NeoplasmGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMalePhosphorylationPromoter Regions, GeneticAndrogen AntagonistsAR protein, humanDihydrotestosteroneReceptors, Androgensrc-Family Kinasesandrogen receptorcastration-recurrent prostate cancercistromeSrctranscriptome

Identifiers

PMID28055971
PMCPMC5354662
OpenAlexW2564696958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.